U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of "serious adverse events", the drug's French maker said on Monday.

The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker Valneva's chikungunya vaccine, saying that continued administration of the vaccine to the public would pose a danger to health.

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S. sales and regulatory review.